SNAI1 Antibody

What is SNAI1 and why is it significant in cancer research?

SNAI1 (Snail homolog 1) is a zinc finger transcriptional repressor that plays a crucial role in epithelial-mesenchymal transition (EMT) and formation of embryonic mesoderm. In cancer research, SNAI1 is particularly significant because it directly represses E-cadherin transcription, promoting tumor invasion and metastasis . Studies have shown that SNAI1 expression is correlated with histological grade and lymph node extension in breast cancers . SNAI1 acts as a key factor in tumor invasion through its ability to repress genes involved in cell-cell adhesion .

In human breast cancer specifically, expression of SNAI1 and/or the homologous SNAI2 (Slug) has been associated with E-cadherin repression, local or distant metastasis, tumor recurrence, and poor prognosis . Furthermore, SNAI1 protein expression in the stroma has been identified as a potential prognostic marker for colon tumors .

What is the expected subcellular localization of SNAI1 protein?

SNAI1 protein displays complex subcellular localization patterns that researchers should be aware of when designing experiments:

• Primary localization: SNAI1 is predominantly found in the nucleus when actively functioning as a transcriptional repressor .

• Secondary localization: SNAI1 can also be detected in the cytoplasm, particularly when phosphorylated .

• Translocation mechanism: Phosphorylation (likely on Ser-107, Ser-111, Ser-115, and Ser-119) triggers export of SNAI1 from the nucleus to the cytoplasm, where subsequent phosphorylation of the destruction motif and ubiquitination involving BTRC occurs .

Immunofluorescence studies using anti-SNAI1 antibodies have confirmed this dual localization pattern. For example, immunofluorescent analysis of HeLa cells shows SNAI1 protein in both cytoplasm and nucleus . When designing experiments, researchers should consider this dynamic localization pattern, as it may reflect different functional states of the protein.

What are the recommended applications for SNAI1 antibodies?

Based on extensive validation data, SNAI1 antibodies have been successfully employed in multiple applications with specific recommendations for optimal results:

Always titrate antibodies in your specific experimental system to determine optimal conditions .

How can I validate the specificity of my SNAI1 antibody?

Antibody validation is crucial for ensuring reliable results in SNAI1 research. Multiple approaches have been documented in the literature:

• Knockout/knockdown controls: Compare wild-type samples with SNAI1 knockout or knockdown samples.

  • Example: Wild-type and SNAI1 knockout HeLa cell extracts were separated by 12% SDS-PAGE, and the membrane was blotted with SNAI1 antibody (GTX125918), showing absence of signal in knockout samples .

• Peptide competition assay: Pre-incubate antibody with blocking peptide.

  • Example: SC10432 antibody was tested after prior incubation with corresponding blocking peptide SC10432P at 1:10 protein ratio versus PBS, demonstrating signal elimination when blocked .

• siRNA treatment: Compare signal in siRNA-treated versus control samples.

  • Example: Immunoblotting performed on SiHa cell lysates treated with SNAI1 siRNA versus control showed decreased signal at ~30 kDa after treatment .

• Multiple antibody comparison: Use different antibodies targeting distinct epitopes.

  • Example: Researchers compared SC10432 and AF3639 antibodies, finding that both labeled the same cell populations, though AF3639 produced stronger nuclear staining with better signal-background ratio .

• Transfection overexpression: Compare transfected versus non-transfected cells.

  • Example: Non-transfected and transfected 293T whole cell extracts were separated by 12% SDS-PAGE, and the membrane was blotted with SNAI1 antibody (GTX125918), showing increased signal in transfected samples .

These validation approaches should be adapted to your specific experimental setup for optimal reliability.

How can I optimize detection of rare SNAI1-positive cells in tumor samples?

Detecting rare SNAI1-positive cells in tumor samples requires special attention to technical details:

Researchers have observed that SNAI1 expression often occurs as an infrequent event in oral squamous cell carcinoma (OSCC), with positive cells representing less than 5% of the tumor population . These rare SNAI1(+) cells are frequently located either near inflammatory sites or close to the invasion front of the tumor . This pattern suggests biological significance despite low abundance.

Optimization strategies include:

• Antibody selection: AF3639 antibody has been reported to produce strong nuclear staining with better signal-to-background ratio compared to SC10432, making it preferable for detecting rare positive cells .

• Careful examination of specific regions: Focus on the invasion front and areas adjacent to inflammation, where SNAI1(+) cells are more likely to be present .

• Threshold setting: Establish appropriate positivity criteria. In one study, SNAI1-positivity was defined as nuclear staining in ≥5% of tumor cells .

• Prognostic significance: Be aware that even rare SNAI1-positive cells may have biological significance. High-level SNAI1 expression (>10% tumor cells) is rare but has been significantly associated with poor outcome in some studies .

• Stromal examination: Always assess SNAI1 expression in the stromal component, as variable SNAI1(+) stroma has been observed in all cases in some studies and may provide additional prognostic information .

What are the methodological considerations for studying SNAI1's role in epithelial-mesenchymal transition (EMT)?

When investigating SNAI1's role in EMT, several methodological approaches have proven valuable:

• Dominant-negative SNAI1 expression models:

  • Comparing invasive breast cancer cells expressing SNAI1 (e.g., MDA-mock) with derived clones expressing dominant-negative forms of SNAI1 (SNAI1-DN) allows investigation of SNAI1's functional role .

  • This approach has revealed that functional blockade of SNAI1 induces partial re-expression of E-cadherin and differential expression of EMT-related genes .

• Analysis of PA system components:

  • SNAI1 activity correlates with expression of plasminogen activator system components, which can be analyzed by:

    • cDNA microarrays

    • Real-time quantitative RT-PCR

  • Research has shown that functional blockade of SNAI1 induces a significant decrease in PAI-1 and uPA transcripts .

• Migration assays:

  • Wound healing assays reveal that SNAI1-DN cells migrate more slowly than SNAI1-expressing cells and in a more collective manner, providing functional validation of EMT status .

• PAI-1 distribution assessment:

  • Immunostaining for PAI-1 shows redistribution in SNAI1-DN cells, decorating large lamellipodia (commonly found structures in these cells) .

  • This contrasts with SNAI1-expressing cells that show more homogeneous PAI-1 distribution .

• Co-expression analysis:

  • Evaluate multiple EMT markers alongside SNAI1, including E-cadherin, FAK, p63, and vimentin.

  • Specific phenotypic patterns (e.g., SNAI1(+)/FAK(+)/E-cadherin(-)/p63(-)) may identify sarcomatoid components within tumors .

These approaches provide complementary information about SNAI1's role in EMT and should be selected based on specific research questions.

What explains the variable molecular weight observed for SNAI1 in Western blot analysis?

The observed molecular weight of SNAI1 in Western blot analysis can vary significantly due to several factors:

• Post-translational modifications:

  • Phosphorylation significantly affects SNAI1's apparent molecular weight. SNAI1 can be phosphorylated on multiple serine residues (likely Ser-107, Ser-111, Ser-115, and Ser-119), which increases its apparent molecular weight .

  • This phosphorylation also regulates SNAI1's subcellular localization, triggering export from the nucleus to the cytoplasm .

• Cell type-specific differences:

  • Different cell lines may express SNAI1 with varying patterns of post-translational modifications, resulting in different apparent molecular weights.

  • When examining various whole cell extracts by Western blot, researchers observe cell type-specific banding patterns .

• Experimental conditions:

  • The percentage of the polyacrylamide gel used for SDS-PAGE can affect migration. Most published protocols recommend 10-12% SDS-PAGE for optimal SNAI1 separation .

  • Different antibodies may recognize distinct forms of SNAI1 with varying efficiency, contributing to perceived molecular weight differences.

• Sample preparation:

  • Proteolytic degradation during sample preparation can generate fragments of varying sizes.

  • Use of phosphatase inhibitors in extraction buffers can preserve phosphorylated forms, potentially affecting observed molecular weight.

Researchers should always run appropriate controls and consider these factors when interpreting SNAI1 Western blot results.

What are the optimal protocols for detecting SNAI1 by immunoblotting?

For optimal detection of SNAI1 by Western blot, the following protocol has been validated across multiple studies:

Sample Preparation and Gel Electrophoresis:

• Prepare whole cell extracts (typically 30-50 μg protein per lane)

• Separate proteins using 10-12% SDS-PAGE

  • 12% gels are recommended for optimal resolution around the 29-35 kDa range where SNAI1 migrates

Transfer and Antibody Incubation:

• Transfer proteins to PVDF or nitrocellulose membrane

• Block with appropriate blocking buffer (typically 5% non-fat milk or BSA in TBST)

• Incubate with primary SNAI1 antibody:

  • For GTX125918: Use 1:500-1:5000 dilution (optimize based on sample type)

  • For 13099-1-AP: Use 1:500-1:1000 dilution

• Wash thoroughly with TBST

• Incubate with appropriate HRP-conjugated secondary antibody:

  • For rabbit primary antibodies: Anti-rabbit IgG (e.g., GTX213110-01)

• Develop signal using enhanced chemiluminescence substrate:

  • Standard ECL for abundant targets

  • Enhanced sensitivity substrates (e.g., Trident ECL plus-Enhanced or Trident femto Western HRP Substrate) for low-abundance targets

Controls and Validation:

• Include positive control lysates from cells known to express SNAI1 (e.g., MCF-7, PC-3, BxPC-3, COLO 320)

• When possible, include SNAI1 knockout/knockdown samples as negative controls

• For antibody validation, compare with competitor antibodies in parallel lanes

Special Considerations:

• Expect a band between 29-35 kDa due to post-translational modifications

• Some antibodies may detect additional bands corresponding to modified SNAI1 forms

• Phosphatase treatment of lysates can confirm phosphorylation-dependent mobility shifts

This protocol has been successfully used to detect SNAI1 in various human and mouse cell lines and tissue samples.

What are the recommended procedures for immunohistochemical detection of SNAI1 in patient samples?

Immunohistochemical detection of SNAI1 in patient samples requires careful attention to protocol details, particularly for antigen retrieval and staining interpretation:

Sample Preparation:

• Fix tissue samples appropriately (typically 10% neutral buffered formalin)

• Process and embed in paraffin

• Cut sections at 4-5 μm thickness

Antigen Retrieval (Critical Step):

• Recommended method: TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0

• Heat-induced epitope retrieval (HIER) is generally more effective than enzymatic retrieval for SNAI1

Staining Protocol:

• Block endogenous peroxidase activity

• Block non-specific binding

• Primary antibody incubation:

  • For 13099-1-AP: Use 1:50-1:500 dilution (optimize for each tissue type)

  • Incubate overnight at 4°C for optimal results

• Secondary antibody detection (according to kit instructions)

• DAB or similar chromogen development

• Counterstain with hematoxylin

• Dehydration and mounting

Controls and Validation:

• Positive controls: Include tissues known to express SNAI1:

  • Human breast carcinoma

  • First trimester human placenta

  • SiHa xenograft tissue from SCID mice

  • Spindle cell carcinoma with vimentin positivity

• Antibody validation: Consider parallel staining with two different antibodies:

  • Researchers have found that both SC10432 and AF3639 label the same cell populations, with AF3639 producing stronger nuclear staining and better signal-background ratio

Interpretation Guidelines:

• Nuclear staining is considered positive for active SNAI1

• Define clear positivity criteria:

  • Some researchers define SNAI1-positivity as nuclear staining in ≥5% of tumor cells

  • High level expression (>10% tumor cells) may have special prognostic significance

• Pay special attention to the invasion front and areas adjacent to inflammation, where rare SNAI1(+) cells are often located

• Always assess stromal SNAI1 expression, as variable SNAI1(+) stroma has been observed in multiple studies

This protocol has been successfully used in various cancer tissues, including breast carcinoma, oral squamous cell carcinoma, and stomach cancer.

What are the optimal techniques for dual detection of SNAI1 and other EMT markers?

For comprehensive analysis of the EMT process, researchers often need to perform dual or multi-marker detection involving SNAI1. Based on the literature, the following methodological approaches are recommended:

Immunofluorescence Co-staining:

• Sample preparation:

  • For cell lines: Fix cells in 4% paraformaldehyde at room temperature for 15 minutes

  • For tissue sections: Use freshly frozen sections or carefully optimized FFPE sections with appropriate antigen retrieval

• Primary antibody combinations:

  • SNAI1 (1:1000 dilution of GTX125918 for cell lines)

  • E-cadherin (epithelial marker)

  • Vimentin (mesenchymal marker)

  • FAK (focal adhesion kinase, often associated with EMT)

  • Additional context-specific markers (β-catenin, ZO-1, etc.)

• Detection strategy:

  • Use primary antibodies from different host species to avoid cross-reactivity

  • Employ fluorophore-conjugated secondary antibodies with non-overlapping emission spectra

  • Include nuclear counterstain (e.g., Hoechst 33342 or DAPI)

• Analysis approach:

  • Capture high-resolution images using confocal microscopy

  • Assess co-localization patterns

  • Quantify signal intensity in different subcellular compartments

Sequential Immunohistochemistry:

For tissues where immunofluorescence is challenging, sequential IHC may be performed:

• First marker staining: Complete standard IHC protocol for SNAI1

• Image capture: Document positive cells/regions

• Antibody stripping: Remove primary and secondary antibodies while preserving tissue architecture

• Second marker staining: Perform IHC for complementary EMT marker

• Co-registration: Align images to identify cells with specific phenotypic patterns

Documented EMT Phenotypes:

Several specific marker combinations have been associated with EMT states in the literature:

• Full EMT phenotype: SNAI1(+)/FAK(+)/E-cadherin(-)/p63(-)

  • This phenotype has been observed in sarcomatoid components of tumors

• Partial EMT states: Various intermediate phenotypes showing co-expression of epithelial and mesenchymal markers

  • These may represent transitional states or context-dependent EMT variants

• Collective migration phenotype:

  • SNAI1-DN cells show more collective behavior compared with SNAI1-expressing cells that tend to migrate individually

  • This phenotype is associated with specific PAI-1 distribution patterns decorating lamellipodia

These techniques allow for sophisticated analysis of the complex and dynamic EMT process in various experimental and clinical contexts.

How do I interpret variable SNAI1 expression patterns in tumor samples?

Interpreting SNAI1 expression in tumor samples requires careful consideration of several factors that influence its expression pattern and biological significance:

Heterogeneous Distribution Patterns:

SNAI1 expression in tumors frequently shows distinctive spatial distribution patterns with biological significance:

• Rare, scattered positive cells:

  • In many tumors, SNAI1-positive cells represent less than 5% of the tumor population

  • These rare cells are often located near inflammatory sites or at the invasion front

  • Despite low frequency, they may have significant biological impact

• Regional expression:

  • SNAI1 is frequently found in the invasive regions of tumors

  • Expression may differ between the main tumor mass and metastatic sites

  • In some cases, primary tumors and corresponding metastases show disparate phenotypes

• Stromal expression:

  • Variable SNAI1-positive stroma has been observed in numerous cases

  • Stromal SNAI1 expression may serve as a prognostic marker independent of tumor cell expression

Prognostic Significance:

Different SNAI1 expression patterns correlate with specific clinical outcomes:

• High expression levels:

  • High-level SNAI1 expression (>10% tumor cells) is rare but significantly associated with poor outcome

  • SNAI1 expression correlates with histological grade and lymph node extension in breast cancers

• Specialized tumor components:

  • SNAI1(+)/FAK(+)/E-cadherin(-)/p63(-) phenotype may identify sarcomatoid components

  • These components may have distinct biological behavior and therapeutic response

Interpretation Challenges:

Several factors complicate interpretation of SNAI1 staining:

• Transient expression: SNAI1 expression may be dynamic during tumor progression

• Context-dependent role: SNAI1 function may vary based on tumor type and microenvironment

• Antibody sensitivity: Different antibodies may detect different subpopulations of SNAI1-expressing cells

• Nuclear vs. cytoplasmic localization: Consider both, as they reflect different functional states

When analyzing SNAI1 expression in tumor samples, researchers should consider these complex patterns and correlate them with other clinicopathological parameters for meaningful interpretation.

What are common troubleshooting strategies for SNAI1 antibody applications?

Despite careful optimization, researchers may encounter challenges when working with SNAI1 antibodies. Here are evidence-based troubleshooting strategies for common issues:

Western Blot Troubleshooting:

Immunohistochemistry/Immunofluorescence Troubleshooting:

Flow Cytometry Troubleshooting:

Validation Approaches:

When troubleshooting persistent issues, consider additional validation strategies:

• Compare multiple antibodies: Different antibodies may perform better in specific applications

• Use genetic controls: SNAI1 knockout/knockdown samples provide definitive negative controls

• Peptide competition: Pre-incubate antibody with blocking peptide to confirm specificity

• Positive controls: Include samples known to express SNAI1 (e.g., specific cancer cell lines)

These strategies have been successfully implemented in published studies to overcome challenges with SNAI1 detection across various experimental platforms.

How do I assess SNAI1 function in relation to its transcriptional targets?

Investigating the functional relationship between SNAI1 and its transcriptional targets requires specialized experimental approaches:

Genetic Manipulation Approaches:

• Dominant-negative SNAI1 expression:

  • Expressing dominant-negative SNAI1 (SNAI1-DN) provides insights into SNAI1's functional role

  • This approach has revealed that functional blockade of SNAI1 leads to:

    • Partial re-expression of E-cadherin

    • Decreased expression of PAI-1 and uPA transcripts

    • Changes in cell migration patterns

• RNA interference:

  • siRNA-mediated knockdown of SNAI1 can confirm antibody specificity

  • It also enables assessment of target gene expression changes

• CRISPR/Cas9 knockout:

  • Comparison of wild-type and SNAI1 knockout cell extracts provides definitive validation

  • Knockout models allow comprehensive analysis of SNAI1-dependent gene expression

Target Gene Analysis:

• E-cadherin regulation:

  • E-cadherin is a direct SNAI1 target and key mediator of epithelial-mesenchymal transition

  • SNAI1 expression is correlated with E-cadherin repression in breast cancers

  • Immunohistochemical analysis can reveal inverse correlation between SNAI1 and E-cadherin expression

• PA system components:

  • PAI-1 and uPA transcript levels decrease upon functional blockade of SNAI1

  • cDNA microarrays and real-time quantitative RT-PCR can quantify these changes

• Comprehensive analysis:

  • cDNA microarrays can identify differential expression of multiple EMT-related genes following SNAI1 manipulation

  • This approach reveals both direct and indirect SNAI1 targets

Functional Readouts:

• Migration assays:

  • Wound healing assays reveal that SNAI1-DN cells migrate more slowly than SNAI1-expressing cells

  • SNAI1-DN cells show more collective migration behavior compared with SNAI1-expressing cells that migrate individually

• PAI-1 redistribution:

  • Blockade of SNAI1 activity results in redistribution of PAI-1 in cells

  • SNAI1-DN cells show PAI-1 decorating large lamellipodia, compared to more homogeneous distribution in SNAI1-expressing cells

• Morphological changes:

  • SNAI1 silencing by stable RNA interference can induce complete mesenchymal to epithelial transition (MET)

  • This is associated with up-regulation of E-cadherin and down-regulation of mesenchymal markers

These approaches provide complementary information about SNAI1's functional role in regulating target genes and cellular processes, particularly in the context of cancer progression and metastasis.

How can SNAI1 antibodies be used to explore the relationship between EMT and cancer therapy resistance?

SNAI1 expression has been implicated in therapy resistance mechanisms in various cancers. Researchers can leverage SNAI1 antibodies to investigate these relationships through:

• Comparative analysis of patient samples:

  • Immunohistochemical staining of pre- and post-treatment tumor samples can reveal therapy-induced changes in SNAI1 expression

  • SNAI1-positive tumor cells, even when representing <5% of the tumor population, may have significant impact on treatment response

  • High-level SNAI1 expression (>10% tumor cells) has been associated with poor outcome

• In vitro resistance models:

  • Western blot analysis of SNAI1 in parental versus drug-resistant cell lines can identify EMT-associated resistance mechanisms

  • Recommended protocol: 10-12% SDS-PAGE with 1:500-1:1000 dilution of SNAI1 antibody

  • Correlate SNAI1 expression with other EMT markers and drug sensitivity profiles

• Functional validation:

  • SNAI1 knockdown or dominant-negative expression in resistant cells can determine if SNAI1 is causally involved in resistance

  • This approach has been used successfully to demonstrate SNAI1's role in various cellular processes

• Pathway analysis:

  • Co-immunoprecipitation using SNAI1 antibodies can identify interaction partners in resistant versus sensitive cells

  • SNAI1 interacts with various corepressors, such as Ajuba, PRMT5, and SIN3a or HDAC1 and 2, to repress target genes

  • These interactions may be therapeutically targetable

• Biomarker development:

  • Multi-parameter analysis combining SNAI1 with other EMT markers (e.g., E-cadherin, FAK, p63) may improve predictive value

  • Specific phenotypic patterns (e.g., SNAI1(+)/FAK(+)/E-cadherin(-)/p63(-)) may identify particularly resistant tumor subpopulations